Itamar Medical’s (NASDAQ: ITMR) (TASE: ITMR) revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue growth by the end of 2019; Itamar Medical has a $6.8B addressable market with limited competition; we start our coverage with a price target of 1.55 NIS.
TEL AVIV, Israel, June 26, 2019 /PRNewswire/ -- Itamar Medical’s (NASDAQ: ITMR) (TASE: ITMR) revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue growth by the end of 2019; Itamar Medical has a $6.8B addressable market with limited competition; we start our coverage with a price target of 1.55 NIS. Equity research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program. You can contact us at no cost to learn more about the companies we cover or to tell us about companies you want covered: equity.research@frost.com Summary of Highlights (read the full report here)
We view Itamar Medical as a growth company with investment potential. Read the full report here. About the Company - Itamar Medical LTD. (NASDAQ: ITMR) (TASE: ITMR) is a publicly traded medical device company that focuses on leading the integration of Sleep Apnea management into the cardiac patient care pathway. The company has one HQ based in Israel’s Caesarea Industrial Park and another in Atlanta Georgia. Since its foundation in 1997, the Company has engaged in research and development of non-invasive medical devices for the diagnosis of various medical conditions, including cardiovascular disease and respiratory disorders. Media Contact: Tiran Rothman
SOURCE Frost & Sullivan | ||
Company Codes: NASDAQ-NMS:ITMR, TelAviv:ITMR |